


## **Supplementary Figures**


**Targeting the Achilles' Heels of Multidrug-Resistant  
*Staphylococcus aureus***  
**by The Endocannabinoid Anandamide**

**Ronit Vogt Sionov, Shreya Banerjee, Sergei Bogomolov,  
Raphael Mechoulam and Doron Steinberg**


### Relative gene expression of AEA-treated MDRSA vs control MDRSA




**Supplementary Figure S1. Effect of AEA on gene expression relevant to antibiotic resistance and biofilm formation.** MDRSA CI-M was incubated in the absence or presence of 50 µg/ml of AEA for 2 h, and then the relative gene expression was determined by quantitative RT-PCR. The data presents a representative experiment where two AEA-treated samples were calculated against two control samples, and using the following 9 housekeeping genes: *gmk*, *glyA*, *gyrA*, *gyrB*, *proC*, *recF*, *rho*, *rpoB*, and *asnC*. \* $p < 0.05$ . The relevant function of these genes are described in *Supplementary Table S1*. Other genes are published in Banerjee et al. *Sci. Rep.* 11: 8690, 2021.




**Supplementary Figure S2.**  
**AEA treatment increases the susceptibility to methyl green.** MDRSA CI-M was exposed to 50 or 25  $\mu$ g/ml AEA for 1 h in TSBG, and then 10  $\mu$ l was spotted on TSA or TSA with 0.02% methyl green, and the plates were incubated overnight at 37°C.






**Supplementary Figure S3. AEA increases cell-bound extracellular DNA.** MDRSA CI-M was exposed to 50 µg/ml AEA for 2 h in TSBG at 37°C, washed in PBS and then exposed to 2 µM TOTO-1 for 20 min at room temperature.



**Supplementary Figure S4.** AEA did not alter the affinity of wheat germ agglutinin (WGA), concanavalin (ConA) or Dextran (average MW 10,000 Dalton) to the bacterial surface. MDRSA CI-M was incubated in the absence or presence of 50 µg/ml of AEA for 2 h, and then the bacteria were incubated with 10 µg/ml of AlexaFluor<sup>647</sup>-conjugated WGA, ConA or Dextran for 20 min prior to analysis by flow cytometry. Grey line: Unstained bacteria; Black line: Control; and Red line: AEA-treated bacteria.

# FtsZ









**Supplementary Figure S5.** LH607 expressing an inducible FtsZ-GFP (SA103; pLOW *ftsZ-gfp*, pGL485 (*erm*<sup>R</sup>, *cat*<sup>R</sup>, *tet*<sup>R</sup>)) was exposed to 50 µM IPTG for 2 h and then incubated in the absence or presence of 50 µg/ml AEA for 2 h and the green fluorescence visualized by spinning disk confocal microscopy.


Control

DivIVA

50 µg/ml AEA 2h



**Supplementary Figure S6.** LH607 expressing inducible DivIVA-GFP (SA356; PdivIVA-gfp::Pspac divIVA, pGL485 (ermR catR tetR)) was exposed to 50 µM IPTG for 2 h and then incubated in the absence or presence of 50 µg/ml AEA for 2 h and the green fluorescence visualized by spinning disk microscopy.









**Supplementary Figure S7.** LH607 expressing EzrA-GFP (SA353; *ezrA::ezrA-gfp*, pGL485 (*erm*<sup>R</sup> *cat*<sup>R</sup>)) was exposed to 50 µM IPTG for 2 h and then incubated in the absence or presence of 50 µg/ml AEA for 2 h and the green fluorescence visualized by spinning disk microscopy.


Control

DnaK

50 µg/ml AEA 2h







**Supplementary Figure S8.** RN4220 expressing inducible DnaK-GFP (SA307; pLOW *dnaK-msgfp*, pGL485 (*erm*<sup>R</sup> *cat*<sup>R</sup>)) was exposed to 50 µM IPTG for 2 h and then incubated in the absence or presence of 50 µg/ml AEA for 2 h and the green fluorescence visualized by spinning disk microscopy.




**Supplementary Figure S9.** Overnight cultures of the various *S. aureus* strains were


resuspended to an OD<sub>600nm</sub> of 0.1 in TSBG and incubated in TSBG for 2 hrs with 50  $\mu$ M IPTG to induce gene expression. Then the bacteria were incubated in the absence or presence of 50  $\mu$ g/ml AEA and the planktonic growth was measured each 10 min for 20 hrs.

**A C A****B****C****D**

**Supplementary Figure S10. Appearance of a high molecular weight protease activity following AEA treatment.** **A. Gelatin zymogram:** SDS-extracts of control or 50 µg/ml AEA (2h)-treated MDRSA CI-M were run in a 5% non-reduced SDS-PAGE containing 1.2 mg/ml gelatin, and following incubation in protease reaction buffer for 24 h at 37°C, the gel was stained with Coomassie blue. A double band clear region was observed in the AEA-treated bacteria in the upper part of the gel representing protein complexes >>250kD. **B-C. Gelatin (B) and casein (C) Zymograms:** MDRSA CI-M that have been exposed to 50 µg/ml AEA and/or 50 µg/m MET for 2h. The upper part of the gel was 7.5%, while the lower part was 15%. Some of the substrate have electrophoresed from the 7.5% gel into the 15% gel. The two lower panels of B and C are black and white images of the two separate parts of the gel. To better visualize the >>250kD proteolytic bands, the images were inverted. In the lower panel, the proteolytic bands appear as clear regions within the gel. **D. Silver stain:** The same samples run in B and C using a 4-15% gradient gel. C=Control; A=AEA; M=MET; AM= AEA+MET. SDS-extraction was done on the same OD of bacteria.

The image of the whole gel of Suppl. Fig. 10A.





**Supplementary Figure S11.** A. Anandamide treatment didn't interfere with secreted protease activity. A-B. MDRSA CI-M was incubated in the absence or presence of 50 µg/ml AEA for 2 h, and then either 10 µl of the bacterial culture (**A**) or 10 µl of the culture supernatant (**B**) were inoculated on TSA agar plates containing 1.5% gelatin. The plates were incubated for 24 h and stained with crystal violet. Clear areas are seen in both control and AEA-treated bacteria indicating the degradation of gelatin by secreted proteases.

**Supplementary Table S1 –Relevant function of genes studied.**

Gene	Relevant gene functions	Reference
<i>abcA</i>	An ATP-dependent transporter that confers resistance to β-lactam antibiotics. <i>abcA</i> is regulated by MgrA, NorG, Rot and sarZ.	[1,2]
<i>airSR</i>	AirSR two-component system is involved in resistance to reactive oxygen species by upregulating Staphyloxanthin production. An <i>airSR</i> <i>Staphylococcus aureus</i> mutant exhibited reduced autolysis rates and reduced viability in the presence of vancomycin.	[3,4]
<i>arlR</i>	The two-component system ArlRS confers oxacillin resistance by inducing the expression of <i>spx</i> . ArlR regulates the expression of more than hundred genes involved in different functions, including autolysis, cell division, growth, and pathogenesis. ArlRS activates MgrA-mediated transcription of genes including cell wall-anchored adhesins ( <i>ebh</i> , <i>sdrD</i> ), polysaccharide and capsule synthesis genes, cell wall remodeling genes ( <i>lytN</i> , <i>ddh</i> ), genes involved in metal transport ( <i>feoA</i> , <i>mnhH</i> , <i>sirA</i> ), anaerobic metabolism genes ( <i>adhE</i> , <i>pflA</i> , <i>nrdDG</i> ) and a large number of virulence factors ( <i>lukSF</i> , <i>lukAB</i> , <i>nuc</i> , <i>gehB</i> , <i>norB</i> , <i>chs</i> , <i>scn</i> and <i>esxA</i> ).	[5-8]
<i>atlA</i>	The initial attachment of <i>S. aureus</i> to a surface depends on the autolysin AtlA. Autolysins promotes the release of extracellular DNA to the biofilm matrix. AtlA is also involved in cell division, cell wall turnover and bacterial lysis.	[9-11]
<i>cida</i>	The CidA murein hydrolase regulator contributes to extracellular DNA release and biofilm formation in <i>Staphylococcus aureus</i> . CidA increases the activity of murein hydrolases and promotes the detachment of bacteria from the biofilm and their spread to new infection sites in the dispersion phase. CidA is a holin that is antagonized by the anti-holin Lrg system.	[12,13]
<i>clpP</i>	Inactivation of ClpXP protease led to increased β-lactam resistance in a MRSA USA300 strain. A truncating mutation in <i>clpP</i> leads to vancomycin resistance. ClpP degrades the autolysin Sle1 required for proper cell division. ClpXP degrades superoxide dismutase (SodA) making the bacteria more prone to cell death. ClpXP degrades the transcription factor Spx that confers antibiotic resistance.	[14-18]
<i>codY</i>	CodY is a nutrient-sensing regulator that affect the expression of over 200 genes. Among others it represses metabolic genes and virulence genes. CodY represses capsule production. A <i>codY</i> mutant is resistant to butyrate-induced growth inhibition. A strain lacking <i>codY</i> regulatory activity produces a PIA-dependent biofilm.	[19-24]
<i>essC</i>	<i>essC</i> encodes a ESAT-6 secretion system C component belonging to the Type VII protein secretion system (T7SS) involved in virulence, EssC possesses a membrane-bound multidomain ATPase and is involved in protein transport.	[25]
<i>fmhB</i>	FmhB is involved in the first step of peptidoglycan pentaglycine interpeptide formation. This interpeptide plays a role in the stability of the <i>S. aureus</i> cell wall, acts as an anchor for cell wall-associated proteins and is essential for methicillin resistance. Any shortening of the pentaglycine side chain reduces or even abolishes methicillin resistance.	[26]
<i>gpsB</i>	GpsB localizes to mid-cell during cell division and interacts with the core divisome component FtsZ. GpsB stimulates the GTPase activity of FtsZ and promotes bundling of FtsZ filaments, thus enabling cell division. Depletion of GpsB caused cell division arrest and cell lysis, whereas overproduction of GpsB led to too early activation of FtsZ, resulting in the formation of enlarged cells.	[27]

<i>isaA</i>	IsaA is a highly immunogenic, noncovalently cell wall-bound lytic transglycosylase that is co-regulated with the glycylglycine endopeptidase LytM. Deletion of <i>isaA</i> in a MRSA strain led to decreased biofilm formation and reduced β-lactam resistance.	[28,29]
<i>lrgAB</i>	LrgA is an anti-holin that antagonizes the activity of murein hydrolases. A <i>lrgAB</i> mutant showed increased extracellular murein hydrolase activity. The <i>lrgAB</i> mutation were more sensitive to penicillin when approaching the stationary phase of growth, the time at which the <i>lrgAB</i> operon is maximally expressed. However, the <i>lrgAB</i> mutation did not affect penicillin-induced killing of cells growing in early-exponential phase, a time in which <i>lrgAB</i> expression is minimal. Inactivation of <i>lrgB</i> increases cell lysis-dependent eDNA release and enhances biofilm formation.	[13,30,31]
<i>luxS</i>	LuxS mutants of <i>S. aureus</i> showed increased biofilm formation, reduced autolysis and increased expression of the vancomycin resistance-associated VraRS two-component regulatory system.	[32-35]
<i>lytSR</i>	LytSR senses changes in the membrane potential and confers resistance to antimicrobial peptides. LytSR is a two-component system that regulates the expression of the anti-holin <i>lrgA</i> and <i>lrgB</i> .	[30,36,37]
<i>mecA</i>	<i>mecA</i> encodes for the PBP2a variant that shows low affinity for β-lactam antibiotics, and thus confers β-lactam resistance.	[38]
<i>pbp4</i>	A penicillin-binding protein that can confer β-lactam resistance, which is thought to be due to its high transpeptidase activity, that results in the production of a highly cross-linked cell wall peptidoglycan.	[1,39,40]
<i>prsA</i>	The foldase PrsA is required for proper folding of PBP2a and thereby promotes β-lactam resistance. Deletion of <i>prsA</i> altered oxacillin resistance and caused a decrease in PBP2A membrane expression without affecting <i>mecA</i> mRNA levels.	[41,42]
<i>saeRS</i>	The SaeRS two component system controls the production of over 20 virulence factors including hemolysins, leukocidins, superantigens, surface proteins, and proteases. SaeRS negatively regulates the expression of genes involved in cytolysis ( <i>lrgA</i> ) and autolysis ( <i>lytS</i> , <i>atlE</i> and <i>aee</i> ). A <i>saeRS</i> mutant showed increase susceptibility to penicillin and oxacillin and was more prone to autolysis.	[43-45]
<i>sasG</i>	The SasG surface protein promotes biofilm formation, especially during the accumulation phase, which requires physiological levels of zinc ions.	[46,47]
<i>sigB</i>	SigB affects biofilm maturation by repressing the expression of RNAIII that has anti-biofilm activities. A <i>sigB</i> mutant showed increased RNAIII expression, elevated extracellular protease levels and altered murine hydrolase activity.	[48]
<i>sle1</i>	The autolysin Sle1 is important for the onset of daughter cell separation. Sle1 is a substrate of the ClpXP protease. High Sle1 levels in bacteria lacking ClpXP activity confer β-lactam hyper-resistance.	[18]
<i>sprX</i>	SprX is a small non-coding RNA that positively regulates the expression of the autolysin regulator WalR, resulting in increased induction of the autolysins <i>isaA</i> and <i>lytM</i> . SprX upregulates the expression of the virulence genes cell wall-associated clumping factor B ( <i>clfB</i> ) and delta hemolysin ( <i>hld</i> ). Down-regulation of <i>sprX</i> resulted in decreased biofilm formation and higher resistance to Triton X-100-induced lysis.	[49,50]
<i>spx</i>	Spx is a stress-induced transcriptional regulator that controls the expression of <i>trfA</i> implicated in antibiotic resistance. Spx expression is regulated by the ArlRS two-component system. Deletion of <i>arlRS</i> sensitized MRSA to oxacillin, while overexpression of Spx in the <i>ΔarlRS</i> strain restored oxacillin resistance.	[5,51-53]

	A <i>spx</i> mutant was hypersensitive to a wide range of stress conditions including high and low temperature, high osmolarity, and hydrogen peroxide due to lack of <i>trxB</i> thioredoxin reductase transcription. YjbH controls the degradation of Spx by ClpP.	
<i>tarO</i>	TarO is involved in the initial step of cell wall teichoic acid synthesis. TagO catalyzes the reversible transfer of GlcNAc-1-P from UDP-GlcNAc to the undecaprenyl phosphate scaffold to produce lipid- $\alpha$ (GlcNAc $\alpha$ -PP-Undecaprenyl). A <i>tagO</i> mutant showed increased cell surface hydrophobicity, enhanced autolytic activity, impaired biofilm formation, and reduced expression of <i>icaADBC</i> and <i>PIA</i> genes. Deletion of <i>tarO</i> in a MRSA strain restored their sensitivity to methicillin.	[54-56]
<i>tarA</i>	TagA is involved in the step after TagO in cell wall teichoic acid synthesis. TagA is a ManNAc transferase that adds ManNAc from a sugar nucleotide donor (UDP-ManNAc), producing a ManNAc ( $\beta$ 1 → 4) GlcNAc $\alpha$ -PP- Undecaprenyl product, called lipid- $\beta$ .	[54]
<i>tarM/tarS</i>	TarM and TarS add $\alpha$ -linked and $\beta$ -linked N-acetylglycosamine, respectively, to the polyribitol chain of the growing wall teichoic acid. Eliminating <i>tarS</i> from a MRSA strain sensitized the bacteria to $\beta$ -lactams. This suggests that $\beta$ -O-GlcNAcylation of wall teichoic acids is required for MRSA resistance.	[54,57]
<i>tarG/tarH</i>	The TagGH transporter transfer the wall teichoic acid across the membrane. TagG is essential for bile-induced biofilm formation in <i>S. aureus</i> and its expression protects the bacteria from bile-induced cell lysis.	[54,58]
<i>trfA</i>	TrfA is required for the degradation of the MazE antitoxin and thus affects dormancy and tolerance to antibiotics. <i>trfA</i> transcription is regulated by the redox sensitive transcriptional factor Spx.	[51,53,59]
<i>walKR</i>	The WalKR two-component system controls cell wall metabolism by regulating autolysin production such as <i>sceD</i> , <i>ssaA</i> , <i>lytM</i> and <i>atlA</i> . A deletion mutation in <i>walRK</i> conferred vancomycin resistance.	[15,60]

**Supplementary Table S2 – Primers used for quantitative real-time PCR for *Staphylococcus aureus*.**

Gene	Forward Primer	Reverse Primer	Reference
16S rRNA	CCAGCAGCCCGGTAAT	CGCGCTTACGCCAATA	[61]
<i>abca</i>	CAAGAACCTATTGAACCGACAGAA	GTGGGATTGGAACGACACA	[1]
<i>airR</i>	TGCTGATGGTTATGAAATGA	CATCTTGCCCTAGGATGT	[19]
<i>airS</i>	TTCTTAGCCAAAATGACAATA	TTCAGTATTGGAGACGCTAC	[19]
<i>arlR</i>	TTCTTCAATATCAAACGGCTTA	GACAACAATCTACACCTAT	[5]
<i>asnC</i>	TCGGTGGATCTGAACGTGTGGA	GTGGCACACTACCATAACGACG	[62]
<i>atlA</i>	AACAGCACCAACGGATTAC	CATAGTCAGCATAGTTATTCAATTG	[49]
<i>cidA</i>	CTACTACTACAACCTAGGAATCATC	TTTACGTAATTCCGAAGC	[63]
<i>clpP</i>	AACAACAAATCGCGGTGAAC	CATAATCGCAAAACAGCTGT	This paper
<i>codY</i>	ATCGCATAAAAGTTGCAGA	CGTGATTCAATTACACCAGCA	[19]
<i>essC</i>	ACCATCGITCGCCAAGGA	TGGCTGTGGCGGTCTTC	[64]
<i>fmhB</i>	AAGCGAGGTACGACAGTAGAACG	CATCTCCATCTCATGCAACGCA	[61]
<i>glyA</i>	CTACAAACTCACAGCCAC	GTATCGGAAGCGGTTATG	[61]
<i>gmk2</i>	CCATCTGGAGTAGGTAAAGG	CTACGCCATCAACTTCAC	[61]
<i>gtf</i>	TGGTGACGCCAAGGACTC	GCAGCACGAGCAGGAACAC	[61]
<i>gpsB</i>	TCCTGAGGTCTTGTGTTGC	TGGCTCGTGGCTATAGAAGA	This paper
<i>gyrA</i>	TGGCCCAAGACTTAGTTATCGTTATCC	TGGGGAGGAATATTGTAGCCATACCTAC	[61]
<i>gyrB</i>	GGTGTGGGCAAATACAAGT	TCCCCACACTAAATGGTGCAA	[61]
<i>isaA</i>	GCAGGTGCTACTGGTCATCAG	GATTACAGAGCAGTATTGC	[49]
<i>lrgA</i>	TGAAACAAACAAAAAGACGCATCAAACAG	ACTTCGCCTAACCTAACAGCACAG	[6]
<i>lrgB</i>	TATTGGTGTGGCCTTCCTC	AAACAGATTGTTGCCGGTT	[63]
<i>luxS</i>	CGGACTACATTCAATTAGAACATT	TTACAAGCAGGCACCTCA	[65]
<i>lytR</i>	ATTAGGAGCTAACGATTCAAAAGATG	TTGACTGCTTGTCAATACG	[63]
<i>lytS</i>	GCATGGTTCTATCGTCGGTACATTG	ACTTACTTGCCTTCGGCTTCAC	[6]
<i>pbp4</i>	CTAAAGGTGAGCAAAGGATAATGG	TCTCTGGATAGTCGCGTGT	[1]
<i>proC</i>	GGCAGGTATTCCGATTGA	CCAGTAACAGAGTGTCCAAC	[61]
<i>prsa</i>	AGTTATGATAAGAAGATTGACGAACAAA	GAAGGGCCTTTCAAATTATCTTT	[42]
<i>recF</i>	AGTTATAGACACGGCACG	GCGTCGTCCTATTGAGG	[61]
<i>rho</i>	GGAAAGATAACGACGTTCAGAC	GAAGCGGGTGGAAAGTTA	[61]
<i>RNAII</i>	TATGAATAAAATGCGCTGATGATATAACCACG	TTTTAAAGTTGATAGACCTAACACGACC	[61]
<i>rpoB</i>	TCCTGTTAACCGCGATGTAA	GCTGGTATGGCTCGTGTGGTA	[61]
<i>saeR</i>	AAGTGGCGACCATTACAT	CATTATTGCCTCAAATACGT	[66]
<i>saeS</i>	TGCCAATACCTTCATCGCTAA	CAATATCGAACGCCACTTGA	[67]
<i>sasG</i>	ATCGTCAGTCACTCATAAC	TATCAACACTCCGTAACC	[65]
<i>sigB</i>	TCGATAACTATAACCAAAGCCT	AAAGTATTGTAAGGACGTCT	[68]
<i>sle1</i>	TCAGGATCTGCAACAACGAC	CCTTTACCAATTTCAGCACGAC	[15]
<i>sprX</i>	ATAATCTTCTAGACGTATTCAAA	CAGGCTATATAGTTCACTCCTACT	[6]
<i>spx</i>	GCTTATTACGTCGTCCAATTATTTA	CGTACGAACCTTTCTAGGTAAGAA	[16]
<i>tarA</i>	GTTGCTGATGGGACAGGAGT	TGCATATTGTGCCGTTCTA	[17]
<i>tarG</i>	ATCAGTATGTGGTCTTCATC	TGCTGCACGGTATGATTCAAG	[17]
<i>tarH</i>	ATCATTGGCGGTTCTTGTC	TGCACGCATACCAACTTGAAT	[17]
<i>tarO</i>	TTCCATCTGCCAAAATA	GAATGGAACGTCTAAAGATAACA	[17]
<i>tarM</i>	TAATGCTAATAATGGTGTG	GGTCCCATCACAAATCATAAT	[18]
<i>tarS</i>	CACGAAACAAGAACGACA	TGATTACCAACACGCAC	[18]
<i>trfA</i>	ATCGAGGCCGTGGATTAG	TCGACACCTTTCAAAGGCA	[4]
<i>walR</i>	CAAATGGCTAGAAAAGTTGTGAG	CAGTAAGCATTATTATTGGCATTTCG	[6]

## References

1. Banerjee, S.; Sionov, R.V., Feldman, M.; Smoum, R.; Mechoulam, R.; Steinberg, D. Anandamide alters the membrane properties, halts the cell division and prevents drug efflux in multidrug resistant *Staphylococcus aureus*. *Sci Rep* **2021**, *11*, 8690.
2. Villet, R.A.; Truong-Bolduc, Q.C.; Wang, Y.; Estabrooks, Z.; Medeiros, H.; Hooper, D.C. Regulation of expression of *abcA* and its response to environmental conditions. *J Bacteriol* **2014**, *196*, 1532-1539.
3. Batte, J.L.; Sahukhal, G.S.; Elasri, M.O. MsaB and CodY interact to regulate *Staphylococcus aureus* capsule in a nutrient-dependent manner. *J Bacteriol* **2018**, *200*, e00294-18.
4. Bai, J.; Zhu, X.; Zhao, K.; Yan, Y.; Xu, T.; Wang, J.; Zheng, J.; Huang, W.; Shi, L.; Shang, Y.; Lv, Z.; Wang, X.; Wu, Y.; Qu, D. The role of ArlRS in regulating oxacillin susceptibility in methicillin-resistant *Staphylococcus aureus* indicates it is a potential target for antimicrobial resistance breakers. *Emerg Microbes Infect* **2019**, *8*, 503-515.
5. Chung, P.Y.; Chung, L.Y.; Navaratnam, P. Transcriptional profiles of the response of methicillin-resistant *Staphylococcus aureus* to pentacyclic triterpenoids. *PLoS One* **2013**, *8*, e56687.
6. Buchad, H.; Nair, M. The small RNA SprX regulates the autolysin regulator WalR in *Staphylococcus aureus*. *Microbiol Res* **2021**, *250*, 126785.
7. Neumann, Y.; Ohlsen, K.; Donat, S.; Engelmann, S.; Kusch, H.; Albrecht, D.; Cartron, M.; Hurd, A.; Foster, S.J. The effect of skin fatty acids on *Staphylococcus aureus*. *Arch Microbiol* **2015**, *197*, 245-267.
8. Ishii, K.; Adachi, T.; Yasukawa, J.; Suzuki, Y.; Hamamoto, H.; Sekimizu, K. Induction of virulence gene expression in *Staphylococcus aureus* by pulmonary surfactant. *Infect Immun* **2014**, *82*, 1500-1510.
9. Liang, X.; Zheng, L.; Landwehr, C.; Lunsford, D.; Holmes, D.; Ji, Y. Global regulation of gene expression by ArlRS, a two-component signal transduction regulatory system of *Staphylococcus aureus*. *J Bacteriol* **2005**, *187*, 5486-5492.
10. Zheng, J.; Shang, Y.; Wu, Y.; Wu, J.; Chen, J.; Wang, Z.; Sun, X.; Xu, G.; Deng, Q.; Qu, D.; Yu, Z. Diclazuril inhibits biofilm formation and hemolysis of *Staphylococcus aureus*. *ACS Infect Dis* **2021**, *7*, 1690-1701.
11. Jousselin, A.; Manzano, C.; Biette, A.; Reed, P.; Pinho, M.G.; Rosato, A.E.; Kelley, W.L.; Renzoni, A. The *Staphylococcus aureus* chaperone PrsA is a new auxiliary factor of oxacillin resistance affecting Penicillin-Binding Protein 2A. *Antimicrob Agents Chemother* **2015**, *60*, 1656-1666.
12. Salaheen, S.; Peng, M.; Joo, J.; Teramoto, H.; Biswas, D. Eradication and sensitization of methicillin resistant *Staphylococcus aureus* to methicillin with bioactive extracts of berry pomace. *Front Microbiol* **2017**, *8*, 253.
13. Sethupathy, S.; Vigneshwari, L.; Valliammai, A.; Balamurugan, K.; Pandian, S.K. L-Ascorbyl 2, 6-Dipalmitate inhibits biofilm and virulence in methicillin-resistant *Staphylococcus aureus* and prevents triacylglyceride accumulation in *Caenorhabditis elegans*. *RSC Adv* **2017**, *7*, 23392-23406.
14. Kannappan, A.; Srinivasan, R.; Nivetha, A.; Annapoorni, A.; Pandian, S.K.; Ravi, A.V. Anti-virulence potential of 2-hydroxy-4-methoxybenzaldehyde against methicillin-resistant *Staphylococcus aureus* and its clinical isolates. *Appl Microbiol Biotechnol* **2019**, *103*, 6747-6758.
15. Wassmann, C.S.; Højrup, P.; Klitgaard, J.K. Cannabidiol is an effective helper compound in combination with bacitracin to kill Gram-positive bacteria. *Sci Rep* **2020**, *10*, 4112.
16. Jousselin, A.; Kelley, W.L.; Barras, C.; Lew, D.P.; Renzoni, A. The *Staphylococcus aureus* thiol/oxidative stress global regulator Spx controls *trfA*, a gene implicated in cell wall antibiotic resistance. *Antimicrob Agents Chemother* **2013**, *57*, 3283-3292.
17. Wanner, S.; Schade, J.; Keinhörster, D.; Weller, N.; George, S.E.; Kull, L.; Bauer, J.; Grau, T.; Winstel, V.; Stoy, H.; Kretschmer, D.; Kolata, J.; Wolz, C.; Bröker, B.M.; Weidenmaier, C. Wall teichoic acids mediate increased virulence in *Staphylococcus aureus*. *Nat Microbiol* **2017**, *2*, 16257.
18. Winstel, V.; Kühner, P.; Salomon, F.; Larsen, J.; Skov, R.; Hoffmann, W.; Peschel, A.; Weidenmaier, C. Wall teichoic acid glycosylation governs *Staphylococcus aureus* nasal colonization. *mBio* **2015**, *6*, e00632.
19. Truong-Bolduc, Q.C.; Hooper, D.C. The transcriptional regulators NorG and MgrA modulate resistance to both quinolones and beta-lactams in *Staphylococcus aureus*. *J Bacteriol* **2007**, *189*, 2996-3005.
20. Hall, J.W.; Yang, J.; Guo, H.; Ji, Y. The *Staphylococcus aureus* AirSR Two-component system mediates reactive oxygen species resistance via transcriptional regulation of Staphyloxanthin production. *Infect Immun* **2017**, *85*, e00838-16.
21. Sun, H.; Yang, Y.; Xue, T.; Sun, B. Modulation of cell wall synthesis and susceptibility to vancomycin by the two-component system AirSR in *Staphylococcus aureus* NCTC8325. *BMC Microbiol* **2013**, *13*, 286.

22. Crosby, H.A.; Tiwari, N.; Kwiecinski, J.M.; Xu, Z.; Dykstra, A.; Jenul, C.; Fuentes, E.J. Horswill, A.R. The *Staphylococcus aureus* ArlRS two-component system regulates virulence factor expression through MgrA. *Mol Microbiol* **2020**, *113*, 103-122.
23. Fournier, B.; Klier, A.; Rapoport, G. The two-component system ArlS-ArlR is a regulator of virulence gene expression in *Staphylococcus aureus*. *Mol Microbiol* **2001**, *41*, 247-261.
24. Heilmann, C.; Hussain, M.; Peters, G.; Götz, F. Evidence for autolysin-mediated primary attachment of *Staphylococcus epidermidis* to a polystyrene surface. *Mol Microbiol* **1997**, *24*, 1013-1024.
25. Houston, P.; Rowe, S.E.; Pozzi, C.; Waters, E.M.; O'Gara, J.P. Essential role for the major autolysin in the fibronectin-binding protein-mediated *Staphylococcus aureus* biofilm phenotype. *Infect Immun* **2011**, *79*, 1153-1165.
26. Bose, J.L.; Lehman, M.K.; Fey, P.D.; Bayles, K.W. Contribution of the *Staphylococcus aureus* Atl AM and GL murein hydrolase activities in cell division, autolysis, and biofilm formation. *PLoS One* **2012**, *7*, e42244.
27. Rice, K.C.; Mann, E.E.; Endres, J.L.; Weiss, E.C.; Cassat, J.E.; Smeltzer, M.S.; Bayles, K.W. The *cidA* murein hydrolase regulator contributes to DNA release and biofilm development in *Staphylococcus aureus*. *Proc Natl Acad Sci U S A* **2007**, *104*, 8113-8118.
28. Ranjit, D.K.; Endres, J.L.; Bayles, K.W. *Staphylococcus aureus* CidA and LrgA proteins exhibit holin-like properties. *J Bacteriol* **2011**, *193*, 2468-2476.
29. Bæk, K.T.; Gründling, A.; Mogensen, R.G.; Thøgersen, L.; Petersen, A.; Paulander, W.; Frees, D. β-Lactam resistance in methicillin-resistant *Staphylococcus aureus* USA300 is increased by inactivation of the ClpXP protease. *Antimicrob Agents Chemother* **2014**, *58*, 4593-4603.
30. Shoji, M.; Cui, L.; Iizuka, R.; Komoto, A.; Neoh, H.M.; Watanabe, Y.; Hishinuma, T.; Hiramatsu, K. *walK* and *clpP* mutations confer reduced vancomycin susceptibility in *Staphylococcus aureus*. *Antimicrob Agents Chemother* **2011**, *55*:3870-3881.
31. Feng, J.; Michalik, S.; Varming, A.N.; Andersen, J.H.; Albrecht, D.; Jelsbak, L.; Krieger, S.; Ohlsen, K.; Hecker, M.; Gerth, U.; Ingmer, H.; Frees, D. Trapping and proteomic identification of cellular substrates of the ClpP protease in *Staphylococcus aureus*. *J Proteome Res* **2013**, *12*, 547-558.
32. Alqarzaee, A.A.; Chaudhari, S.S.; Islam, M.M.; Kumar, V.; Zimmerman, M.C.; Saha, R.; Bayles, K.W.; Frees, D.; Thomas, V.C. Staphylococcal ClpXP protease targets the cellular antioxidant system to eliminate fitness-compromised cells in stationary phase. *Proc Natl Acad Sci U S A* **2021**, *118*, e2109671118.
33. Thalsø-Madsen, I.; Torrubia, F.R.; Xu, L.; Petersen, A.; Jensen, C.; Frees, D. The Sle1 cell wall amidase is essential for β-Lactam resistance in community-acquired methicillin-resistant *Staphylococcus aureus* USA300. *Antimicrob Agents Chemother* **2019**, *64*, e01931-19.
34. Fletcher, J.R.; Villareal, A.R.; Penningroth, M.R.; Hunter, R.C. *Staphylococcus aureus* overcomes anaerobe-derived short-chain fatty acid stress via FadX and the CodY regulon. *J Bacteriol* **2022**, e0006422.
35. Pohl, K.; Francois, P.; Stenz, L.; Schlink, F.; Geiger, T.; Herbert, S.; Goerke, C.; Schrenzel, J.; Wolz, C. CodY in *Staphylococcus aureus*: A regulatory link between metabolism and virulence gene expression. *J Bacteriol* **2009**, *191*, 2953-2963.
36. Majerczyk, C.D.; Sadykov, M.R.; Luong, T.T.; Lee, C.; Somerville, G.A.; Sonenshein, A.L. *Staphylococcus aureus* CodY negatively regulates virulence gene expression. *J Bacteriol* **2008**, *190*, 2257-2265.
37. Waters, N.R.; Samuels, D.J.; Behera, R.K.; Livny, J.; Rhee, K.Y.; Sadykov, M.R.; Brinsmade, S.R. A spectrum of CodY activities drives metabolic reorganization and virulence gene expression in *Staphylococcus aureus*. *Mol Microbiol* **2016**, *101*, 495-514.
38. Majerczyk, C.D.; Dunman, P.M.; Luong, T.T.; Lee, C.Y.; Sadykov, M.R.; Somerville, G.A.; Bodi, K.; Sonenshein, A.L. Direct targets of CodY in *Staphylococcus aureus*. *J Bacteriol* **2010**, *192*, 2861-2877.
39. Bowman, L.; Palmer, T. The Type VII Secretion System of *Staphylococcus*. *Annu Rev Microbiol* **2021**, *75*, 471-494.
40. Rohrer, S.; Ehlert, K.; Tschierske, M.; Labischinski, H.; Berger-Bächi, B. The essential *Staphylococcus aureus* gene *fmhB* is involved in the first step of peptidoglycan pentaglycine interpeptide formation. *Proc Natl Acad Sci U S A* **1999**, *96*, 9351-9356.
41. Eswara, P.J.; Brzozowski, R.S.; Viola, M.G.; Graham, G.; Spanoudis, C.; Trebino, C.; Jha, J.; Aubee, J.I.; Thompson, K.M.; Camberg, J.L.; Ramamurthi, K.S. An essential *Staphylococcus aureus* cell division protein directly regulates FtsZ dynamics. *Elife* **2018**, *7*, e38856.
42. Lopes, A.A.; Yoshii, Y.; Yamada, S.; Nagakura, M.; Kinjo, Y.; Mizunoe, Y.; Okuda, K.I. Roles of lytic transglycosylases in biofilm formation and β-lactam resistance in methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* **2019**, *63*, e01277-19.

43. Stapleton, M.R.; Horsburgh, M.J.; Hayhurst, E.J.; Wright, L.; Jonsson, I.M.; Tarkowski, A.; Kokai-Kun, J.F.; Mond, J.J.; Foster, S.J. Characterization of IsaA and SceD, two putative lytic transglycosylases of *Staphylococcus aureus*. *J Bacteriol* **2007**, *189*, 7316-7325.
44. Groicher, K.H.; Firek, B.A.; Fujimoto, D.F.; Bayles, K.W. The *Staphylococcus aureus* *lrgAB* operon modulates murein hydrolase activity and penicillin tolerance. *J Bacteriol* **2000**, *182*, 1794-1801.
45. Beltrame, C.O.; Côrtes, M.F.; Bonelli, R.R.; Córrea, A.B.; Botelho, A.M.; Américo, M.A.; Fracalanza, S.E.; Figueiredo, A.M. Inactivation of the autolysis-related genes *lrgB* and *ycaI* in *Staphylococcus aureus* increases cell lysis-dependent eDNA release and enhances biofilm development *in vitro* and *in vivo*. *PLoS One* **2015**, *10*, e0138924.
46. Yu, D.; Zhao, L.; Xue, T.; Sun, B. *Staphylococcus aureus* autoinducer-2 quorum sensing decreases biofilm formation in an *icaR*-dependent manner. *BMC Microbiol* **2012**, *12*, 288.
47. Xue, T.; Zhao, L.; Sun, B. LuxS/AI-2 system is involved in antibiotic susceptibility and autolysis in *Staphylococcus aureus* NCTC 8325. *Int J Antimicrob Agents* **2013**, *41*, 85-89.
48. Ma, R.; Qiu, S.; Jiang, Q.; Sun, H.; Xue, T.; Cai, G.; Sun, B. AI-2 quorum sensing negatively regulates *rbf* expression and biofilm formation in *Staphylococcus aureus*. *Int J Med Microbiol* **2017**, *307*, 257-267.
49. Zhao, L.; Xue, T.; Shang, F.; Sun, H.; Sun, B. *Staphylococcus aureus* AI-2 quorum sensing associates with the KdpDE two-component system to regulate capsular polysaccharide synthesis and virulence. *Infect Immun* **2010**, *78*, 3506-3515.
50. Yang, S.J.; Xiong, Y.Q.; Yeaman, M.R.; Bayles, K.W.; Abdelhady, W.; Bayer, A.S. Role of the LytSR two-component regulatory system in adaptation to cationic antimicrobial peptides in *Staphylococcus aureus*. *Antimicrob Agents Chemother* **2013**, *57*, 3875-3882.
51. Brunskill, E.W.; Bayles, K.W. Identification and molecular characterization of a putative regulatory locus that affects autolysis in *Staphylococcus aureus*. *J Bacteriol* **1996**, *178*, 611-618.
52. Peacock, S.J.; Paterson, G.K. Mechanisms of methicillin resistance in *Staphylococcus aureus*. *Annu Rev Biochem* **2015**, *84*, 577-601.
53. da Costa, T.M.; de Oliveira, C.R.; Chambers, H.F.; Chatterjee, S.S. PBP4: A new perspective on *Staphylococcus aureus* β-lactam resistance. *Microorganisms* **2018**, *6*, 57.
54. Hamilton, S.M.; Alexander, J.A.N.; Choo, E.J.; Basuino, L.; da Costa, T.M.; Severin, A.; Chung, M.; Aedo, S.; Strynadka, N.C.J.; Tomasz, A.; Chatterjee, S.S.; Chambers, H.F. High-level resistance of *Staphylococcus aureus* to β-Lactam antibiotics mediated by Penicillin-Binding Protein 4 (PBP4). *Antimicrob Agents Chemother* **2017**, *61*, e02727-16.
55. Roch, M.; Lelong, E.; Panasenko, O.O.; Sierra, R.; Renzoni, A.; Kelley, W.L. Thermosensitive PBP2a requires extracellular folding factors PrsA and HtrA1 for *Staphylococcus aureus* MRSA β-lactam resistance. *Commun Biol* **2019**, *2*, 417.
56. Liu, Q.; Yeo, W.S.; Bae, T. The SaeRS two-component system of *Staphylococcus aureus*. *Genes (Basel)* **2016**, *7*, 81.
57. Lou, Q.; Ma, Y.; Qu, D. Two-component signal transduction system SaeRS is involved in competence and penicillin susceptibility in *Staphylococcus epidermidis*. *J Basic Microbiol* **2016**, *56*, 358-368.
58. Lou, Q.; Zhu, T.; Hu, J.; Ben, H.; Yang, J.; Yu, F.; Liu, J.; Wu, Y.; Fischer, A.; Francois, P.; Schrenzel, J.; Qu, D. Role of the SaeRS two-component regulatory system in *Staphylococcus epidermidis* autolysis and biofilm formation. *BMC Microbiol* **2011**, *11*, 146.
59. Geoghegan, J.A.; Corrigan, R.M.; Gruszka, D.T.; Spezzale, P.; O'Gara, J.P.; Potts, J.R.; Foster, T.J. Role of surface protein SasG in biofilm formation by *Staphylococcus aureus*. *J Bacteriol* **2010**, *192*, 5663-5673.
60. Formosa-Dague, C.; Spezzale, P.; Foster, T.J.; Geoghegan, J.A.; Dufrêne, Y.F. Zinc-dependent mechanical properties of *Staphylococcus aureus* biofilm-forming surface protein SasG. *Proc Natl Acad Sci U S A* **2016**, *113*, 410-415.
61. Lauderdale, K.J.; Boles, B.R.; Cheung, A.L.; Horswill, A.R. Interconnections between Sigma B, *agr*, and proteolytic activity in *Staphylococcus aureus* biofilm maturation. *Infect Immun* **2009**, *77*, 1623-1635.
62. Kathirvel, M.; Buchad, H.; Nair, M. Enhancement of the pathogenicity of *Staphylococcus aureus* strain Newman by a small noncoding RNA SprX1. *Med Microbiol Immunol* **2016**, *205*, 563-574.
63. Pamp, S.J.; Frees, D.; Engelmann, S.; Hecker, M.; Ingmer, H. Spx is a global effector impacting stress tolerance and biofilm formation in *Staphylococcus aureus*. *J Bacteriol* **2006**, *188*, 4861-4870.
64. Panasenko, O.O.; Bezrukova, F.; Komarynets, O.; Renzoni, A. YjbH solubility controls Spx in *Staphylococcus aureus*: Implication for MazEF Toxin-Antitoxin system regulation. *Front Microbiol* **2020**, *11*, 113.
65. Brown, S.; Santa Maria, J.P.Jr.; Walker, S. Wall teichoic acids of gram-positive bacteria. *Annu Rev Microbiol* **2013**, *67*, 313-336.

66. Holland, L.M.; Conlon, B.; O'Gara, J.P. Mutation of *tagO* reveals an essential role for wall teichoic acids in *Staphylococcus epidermidis* biofilm development. *Microbiology (Reading)* **2011**, *157*, 408-418.
67. Farha, M.A.; Leung, A.; Sewell, E.W.; D'Elia, M.A.; Allison, S.E.; Ejim, L.; Pereira, P.M.; Pinho, M.G.; Wright, G.D.; Brown, E.D. Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to  $\beta$ -lactams. *ACS Chem Biol* **2013**, *8*, 226-233.
68. Brown, S.; Xia, G.; Luhachack, L.G.; Campbell, J.; Meredith, T.C.; Chen, C.; Winstel, V.; Gekeler, C.; Irazoqui, J.E.; Peschel, A.; Walker, S. Methicillin resistance in *Staphylococcus aureus* requires glycosylated wall teichoic acids. *Proc Natl Acad Sci U S A* **2012**, *109*, 18909-18914.
69. Ulluwishewa, D.; Wang, L.; Pereira, C.; Flynn, S.; Cain, E.; Stick, S.; Reen, F.J.; Ramsay, J.P.; O'Gara, F. Dissecting the regulation of bile-induced biofilm formation in *Staphylococcus aureus*. *Microbiology* **2016**, *162*, 1398-1406.
70. Donegan, N.P.; Marvin, J.S.; Cheung, A.L. Role of adaptor TrfA and ClpPC in controlling levels of SsrA-tagged proteins and antitoxins in *Staphylococcus aureus*. *J Bacteriol* **2014**, *196*, 4140-4151.
71. Poupel, O.; Proux, C.; Jagla, B.; Msadek, T.; Dubrac, S. SpdC, a novel virulence factor, controls histidine kinase activity in *Staphylococcus aureus*. *PLoS Pathog* **2018**, *14*, e1006917.